Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02455804 · ClinicalTrials.gov registry record · NA
NIRTRAKS Post-Market Study (NIRTRAKS)
A NA study, sponsored by Medinol.
- Completed
- Registry status
- NA
- Development phase
- 65
- Enrollment target
NCT02455804 is a NA study that has completed, run by Medinol. The registered enrollment target is 65 participants.
The verdict
NCT02455804, a NA study, has completed, sponsored by Medinol.
- COMPLETED
- Registry status
- NA
- Development phase
- 65 participants
- Enrollment target
Study Summary
This is a prospective, post-marketing, non-randomized, multi-center, single-arm clinical study that will be conducted at up to 15 sites in the United States (US). All subjects will be treated with the NIRxcell Stent System and followed at 30 days, 9 months and 1, 2 and 3 years post-index stenting procedure. An unscheduled follow up may be conducted as clinically warranted.
Interventions
- DEVICE Stenting procedure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2016-01-08 |
| Est. Completion | 2020-01-14 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02455804
The ClinicalTrials.gov registry entry for NCT02455804 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medinol, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Stenting procedure is the first listed.
NCT02455804 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02455804 about?
NCT02455804 is a clinical study titled "NIRTRAKS Post-Market Study (NIRTRAKS)". This is a prospective, post-marketing, non-randomized, multi-center, single-arm clinical study that will be conducted at up to 15 sites in the United States (US). All subjects will be treated with the NIRxcell Stent System and followed at 30 days, 9 months and 1, 2 and 3 years post-index stenting pr...
What is the current status of trial NCT02455804?
This trial is currently completed. It is a NA study. The enrollment target is 65 participants. The study started on 2016-01-08. Estimated completion is 2020-01-14.
What interventions are being tested in trial NCT02455804?
The interventions under investigation include: Stenting procedure (DEVICE).
Who is sponsoring clinical trial NCT02455804?
This trial is sponsored by Medinol, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.